Hacker News Reader

That's a good article with a good point. As a caregiver impatiently waiting for Daraxonrasib, I can at least acknowledge that the institutional machinery is going as fast as it can. I've litterally witnessed a trial patient in the first cohort of a drug (that went no further) be rushed from infusion to the hospital; the trial process cannot be sped up from its current state without endangering lives.

View on HN

> As a caregiver impatiently waiting for Daraxonrasib

Same here. Are you and your care recipient familiar with the Optune Pax device that the FDA approved in February?

https://www.fda.gov/news-events/press-announcements/fda-appr...

My father's been using it since April. It's a little cumbersome and only improves overall survival rates by about two months over chemo alone, but we're hoping that it helps him remain relatively healthy until Daraxonrasib becomes available.

Thanks for that. I wasn't aware. She doesn't repond well to that regimen, so it doesn't apply to us.

We should be alright. We're on track for the expanded access program. Also, it's a long story, but she was taken off an Irinotecan-containing regimen prematurely about a year ago. In hindsight, she was clearly reaponding very well to that particular drug, so we've got that in our toolkit.

Reply on news.ycombinator.com